Lilly's Zepbound outlook is now growing faster than Zepbound

Eli Lilly will raise its full-year outlook every Monday from now on, and investors will pay to find out by how much. The drugmaker calls the product Guidance+. It launches with fourteen scheduled raises between now and the end of the year.

The move follows a third outlook hike this year, driven by Zepbound, which keeps dominating the U.S. market for prescription weight-loss drugs. Executives looked at three raises and saw a company leaving upside on the table. "Quarterly guidance is a fax machine," said Chief Outlook Officer Brayden Kessler-Vance. "We are going weekly, we are going recurring, and we are going premium."

Let me be clear about what this is. This is a generational unlock. Nobody else in pharma has thought to decouple the forecast from the thing being forecast, and Lilly just did it on a Monday.

The tiers are simple. Basic subscribers get the raise Monday morning with everyone else. Pro subscribers get it Sunday night. Platinum subscribers join a group call and co-create the number. "It is guidance, but it is also community," Kessler-Vance said.

Asked how the outlook now relates to actual sales, he was candid. "Legacy guidance was coupled to revenue. We have decoupled it. The number is a product now, and the product goes up." Asked what the number would be, he said that was the paywall.

"Fourteen raises in nine weeks? That is a company that respects my time."

The street loves it. Tucker Blankenship, who runs Thrust Capital, said the old cadence had started to feel stingy. "I have been long Lilly for years and three raises a year was honestly disrespectful," he said. He bought Platinum on day one and plans to pitch the first number himself. He described it as "something with a lot of nines in it."

Regulators have not weighed in. A company spokesperson said they "have not said no yet, which in our culture we read as a yes." Compliance, she added, has been moved under Growth.

Guidance on the guidance

Lilly also confirmed it has pre-raised its 2027 outlook, then raised the raise. Kessler-Vance called this "guidance squared" and said a 2028 figure is in beta. He would not share it. Platinum members saw it Sunday.

There is one open question, and the company is leaning in. The outlook is now Lilly's fastest-growing line item, ahead of the drug that produced it. "It has put on a lot of size very quickly," Kessler-Vance said. "We are looking at whether the outlook itself qualifies for a GLP-1 program. Early signals are strong."

Shares, I am told, are up. Guidance on that is available Monday.